ArticleVaccine2024

Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].

Shoroq M Altawalbeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.